[{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"c28173c9-ac67-4f97-95aa-85bf990befb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052555","created_at":"2021-01-18T19:52:14.840Z","updated_at":"2025-02-25T13:39:55.670Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04052555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2025-02-21"},{"id":"78af9b6a-0b92-4e92-b86c-385f5f7643c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04266912","created_at":"2021-01-18T20:43:57.460Z","updated_at":"2025-02-25T14:15:34.609Z","phase":"Phase 1/2","brief_title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","source_id_and_acronym":"NCT04266912","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"81538df4-516d-49a5-ada8-8fcdc290500e","acronym":"NCI 9938","url":"https://clinicaltrials.gov/study/NCT02595931","created_at":"2021-07-05T16:47:22.525Z","updated_at":"2024-07-02T16:34:37.311Z","phase":"Phase 1","brief_title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02595931 - NCI 9938","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/22/2016","start_date":" 07/22/2016","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"4d56170f-3d3b-4047-a1c3-ff6755434589","acronym":"","url":"https://clinicaltrials.gov/study/NCT03641313","created_at":"2021-01-18T17:53:13.421Z","updated_at":"2024-07-02T16:35:03.317Z","phase":"Phase 2","brief_title":"Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03641313","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • MSI","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • MSI-H/dMMR","tags":["HER-2 • TP53 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-16"},{"id":"74fab00e-e59b-494f-917f-dc80d3cf68bd","acronym":"NCI-2015-01779","url":"https://clinicaltrials.gov/study/NCT02589522","created_at":"2024-03-25T19:35:37.933Z","updated_at":"2024-07-02T16:35:12.957Z","phase":"Phase 1","brief_title":"Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors","source_id_and_acronym":"NCT02589522 - NCI-2015-01779","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 08/23/2021","primary_completion_date":" 08/23/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"c14e2d3d-2408-48c9-8ec6-22c81595ada5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487095","created_at":"2021-01-18T11:59:05.036Z","updated_at":"2024-07-02T16:35:16.360Z","phase":"Phase 1/2","brief_title":"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers","source_id_and_acronym":"NCT02487095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/30/2015","start_date":" 07/30/2015","primary_txt":" Primary completion: 02/24/2021","primary_completion_date":" 02/24/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-03-05"},{"id":"8dffbd9d-b6f2-4682-a5ca-cd6146347859","acronym":"TARSARC","url":"https://clinicaltrials.gov/study/NCT04807816","created_at":"2021-03-19T15:59:15.779Z","updated_at":"2025-02-25T16:11:16.285Z","phase":"Phase 2","brief_title":"Targeting ATR in Soft-tissue Sarcomas","source_id_and_acronym":"NCT04807816 - TARSARC","lead_sponsor":"Institut Bergonié","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • berzosertib (M6620)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-09-28"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"765202f9-373b-4937-9117-32ae82f21dac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02723864","created_at":"2021-01-18T13:19:41.499Z","updated_at":"2024-07-02T16:36:17.432Z","phase":"Phase 1","brief_title":"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors","source_id_and_acronym":"NCT02723864","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51 • NBN","pipe":"","alterations":" ","tags":["RAD51 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888) • berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-02-08"},{"id":"57e1a256-5bfa-4ba0-ac14-8f8018a90dd1","acronym":"MS201943_0029","url":"https://clinicaltrials.gov/study/NCT03704467","created_at":"2021-01-18T18:09:09.779Z","updated_at":"2025-02-25T16:08:27.986Z","phase":"Phase 1","brief_title":"Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer","source_id_and_acronym":"NCT03704467 - MS201943_0029","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Bavencio (avelumab) • berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 11/06/2019","primary_completion_date":" 11/06/2019","study_txt":" Completion: 11/06/2019","study_completion_date":" 11/06/2019","last_update_posted":"2020-11-13"},{"id":"3c90f7b1-0c35-4491-9663-bd8394693c86","acronym":"MS201923_0001","url":"https://clinicaltrials.gov/study/NCT02157792","created_at":"2021-01-18T10:02:17.956Z","updated_at":"2025-02-25T16:13:53.639Z","phase":"Phase 1","brief_title":"M6620 First in Human Study","source_id_and_acronym":"NCT02157792 - MS201923_0001","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative • BRCA wild-type","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • etoposide IV • irinotecan • berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2012","start_date":" 12/10/2012","primary_txt":" Primary completion: 03/11/2020","primary_completion_date":" 03/11/2020","study_txt":" Completion: 03/11/2020","study_completion_date":" 03/11/2020","last_update_posted":"2020-04-01"}]